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Abstract GEP-NENs are a challenging family of tumors
of growing incidence and varied clinical management and
behavior. Diagnostic techniques have substantially
improved over the past decades and significant advances
have been achieved in the understanding of the molecular
pathways governing tumor initiation and progression. This
has already translated into relevant advances in the clinic.
This guideline aims to provide practical recommendations
for the diagnosis and treatment of GEP-NENs. Diagnostic
workup, histological and staging classifications, and the
different available therapeutic approaches, including sur-
gery, liver-directed ablative therapies, peptide receptor
radionuclide therapy, and systemic hormonal, cytotoxic or
targeted therapy, are briefly discussed in this manuscript.
Clinical presentation (performance status, comorbidities,
tumor-derived symptoms and hormone syndrome in func-
tioning tumors), histological features [tumor differentia-
tion, proliferation rate (Ki-67), and expression of
somatostatin receptors], disease localization and extent,
and resectability of primary and metastatic disease, are all
key issues that shall be taken into consideration to appro-
priately tailor therapeutic strategies and surveillance of
these patients.
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Introduction
The incidence of NENs in the Caucasian population has
substantially increased over the past three decades from
1.09 (1973) to 5.76 (2007) new cases per 100,000 inhab-
itants annually. About two-thirds of NENs are of gastro-
intestinal or pancreatic origin (GEP-NENs), and, among
these, the most common site of origin is the small intestine
[1–4]. Although GEP-NENs represent only 2 % of all
gastrointestinal tumors, their prevalence is rather high due
to their relatively long survival, being the second most
prevalent gastrointestinal malignancy after colorectal
adenocarcinoma.
NENs are diagnosed at a younger age than carcinomas,
usually during the fifth decade of life, and they may arise
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sporadically or as a result of hereditary predisposition
syndromes such as multiple endocrine neoplasia type 1
(MEN-1) or Von Hippel–Lindau’s disease (VHL). Clinical
onset in patients with genetic predisposition may occur
15 years earlier. About one-third are so-called functioning
tumors, a unique feature that is the consequence of excess
hormone production by the tumor. The rate of metastatic
disease at presentation widely ranges in different tumor
registries from 27 to 73 % [1–4]. Overall survival rates
may also significantly vary from 30 to 90 % at 5 years,
depending upon the distribution of a number of prognostic
factors, the most relevant being the primary tumor site,
stage of disease, histological differentiation and prolifera-
tive index (Ki-67 or mitotic index). A pancreatic origin,
followed by the colon, is the primary tumor site with the
worst prognosis among GEP-NETs [1].
The wide range of histological, biochemical and clinical
behavior of these tumors may require very diverse diag-
nostic and therapeutic approaches, including surgery, liver-
directed ablative techniques, peptide receptor radionuclide
therapy (PRRT), and/or systemic hormonal, cytotoxic or
targeted therapies. The aim of the current manuscript is to
provide synthetic practical guidelines regarding diagnostic
procedures and therapeutic options for the multidisciplin-
ary management of NENs of gastrointestinal or pancreatic
origin.
Diagnostic procedures
NENs originate in a great diversity of tissues and are
characterized by their ability to produce different peptides
that cause distinct hormonal syndromes (Table 1). Based
on this, they are broadly subdivided into ‘‘functional’’ or
‘‘nonfunctional’’ tumors (with or without a clinical syn-
drome). Most well-differentiated neuroendocrine tumors
(NETs) arise from the gut or bronchopulmonary system,
formerly called carcinoid tumors. Current nomenclature
guidelines do not support this term, to avoid confusion
between tumor type and the functional syndrome. Carci-
noid is also a generic term for a characteristic syndrome
that results from the intermittent release of bioactive
amines (serotonin and others) into the systemic circulation
that occurs in some patients with NETs.
The most frequent functionally active neuroendocrine
tumors are, besides carcinoids, insulinoma, gastrinoma,
vasoactive intestinal polypeptidoma (VIPoma) and gluca-
gonoma. Non-functional tumors are often clinically silent
until late advanced disease. Although these neoplasms are
generally more indolent than carcinomas, they often have
unpredictable biological behavior and may sometimes
present very aggressive clinical course. Given the rarity,
heterogeneous and unique nature of these neoplasms, it is
highly recommended to refer these patients to specialized
centres.
In order to appropriately diagnose and stage GEP-NENs
the following procedures are recommended:
– Medical history and physical examination.
– Laboratory tests, including hematological, liver and
renal function tests.
– General hormonal markers: chromogranin A (NETs),
neurospecific enolase (NECs).
– Specific hormonal markers: urinary 5-hydroxyindole-
acetic acid (5-HIAA) (carcinoid syndrome); gas-
trin ± secretin test (gastrinomas); insulin/glucose
ratio, proinsulin, C peptide (insulinomas), glucagon,
VIP and others depending upon clinical symptoms.
– Tumor specimen or biopsy: the histopathological report
shall provide the WHO classification and TNM staging
[5–8]. Inmunohistochemical staining should always
include Ki-67 (% of positive cells assessed in 2,000
tumor cells in areas of highest nuclear labeling) and
general neuroendocrine markers (chromogranin A,
synaptophysin and neuron-specific enolase) [9]. Spe-
cific markers are not mandatory and should only be
Table 1 Clinical features associated with excess hormone production in GEP-NETs
Tumor Hormone Islet cell
type
Clinical syndrome
Carcinoid Serotonin Flushing, diarrhea, bronchospasm, tricuspid or pulmonary valve insufficiency or stenosis
Gastrinoma Gastrin c Zollinger–Ellison syndrome: recurrent peptic ulcer, diarrhea/steatorrhea
Insulinoma Insulin b Hypoglycemia, catecholamine excess
Glucagonoma Glucagon a Diabetes mellitus, migratory necrolytic erythema, panhypoaminoaciduria, thromboembolism,
weight loss
VIPoma VIP d Verner–Morrison syndrome (WDHA): watery diarrhea, hypokalemia, achlorhydria, metabolic
acidosis, hyperglycemia, hypercalcemia, flushing
Somatostatinoma Somatostatin d Diabetes mellitus, diarrhea/steatorrhea, hypochlorhydria, weight loss, gall bladder disease
PPoma PP PP cells Hepatomegaly, abdominal pain, occasional watery diarrhea
PTHoma PTH-rp Hypercalcemia
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performed if clinically indicated (insulin, glucagon,
etc).
– Somatostatin receptor scintigraphy (octreoscan). This
may be replaced by new diagnostic techniques with
improved resolution, such as 68Gallium-DOTA-TOC/-
NOC/-TATE positron emission tomography (PET),
wherever available.
– Dynamic CT scan of the abdomen.
– Chest X-ray. A thoracic CT scan may be considered in
poorly differentiated tumors, colon primaries or those
in whom surgery of liver metastasis is being
considered.
– Genetic counseling in hereditary predisposition syn-
dromes (MEN-1, VHL, tuberous sclerosis, and neuro-
fibromatosis, among others).
Depending upon clinical presentation and primary tumor
site the following procedures may be also considered:
– Oral endoscopy, enteroscopy, capsule endoscopy,
endoscopic ultrasound, colonoscopy.
– 18-Fluorodeoxyglucose-(FDG-) PET (poorly differen-
tiated NEC metastasis of unknown primary; no use in
low grade tumors).
– Echocardiogram (carcinoid syndrome).
– N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
may be also considered if carcinoid heart disease is
suspected.
– Brain CT or bone scan (only if bone pain, neurological
symptoms, etc).
Classification and staging systems
Recent international efforts are helping to improve the
prognostic classifications of this type of tumors and to
better tailor therapeutic strategies in these patients. In this
context, the recently updated 2010 WHO classification has
been a major step forward as a worldwide expert consensus
for a standardized taxonomy of this heterogeneous disease
[5]. The WHO classification has endorsed the European
Neuroendocrine Tumor Society (ENETS) grading system,
and discerns two major NEN pathological categories with
important therapeutic and prognostic implications: well-
differentiated neuroendocrine tumors (NETs G1 and G2)
and poorly differentiated neuroendocrine carcinomas
(NECs G3) (Table 2). Less worldwide consensus exists
regarding staging of these neoplasms. Indeed, two TNM
staging systems have been proposed (ENETS and AJCC/
UICC) [6–8], that have relevant differences in certain
subgroups of NENs including those of pancreatic or
appendiceal origin (Table 3). In addition, the ENETS
proposal stages poorly differentiated NECs as well-
differentiated NETs, while the AJCC system stages poorly
differentiated NECs as adenocarcinomas. The unification
of these staging systems is therefore a relevant pending
issue that will likely require solid multi-institutional data
for adequate and consistent validation.
Therapy
Surgery
Surgery is the only potentially curative therapeutic strategy
in localized disease. Radical oncological surgery is indi-
cated except for small carcinoids (\2 cm) of the stomach,
appendix or rectum, in which more conservative surgical or
endoscopic resections may be appropriate due to their low
malignant potential. Small pancreatic insulinomas also
have a very good prognosis (90 % are benign tumors) and
tumor enucleation is generally sufficient [3, 4]. No adju-
vant therapy is recommended in completely resected well-
differentiated localized NETs. Adjuvant chemotherapy
with platinum and etoposide may be considered in poorly
differentiated tumors, although evidence supporting this
strategy is lacking.
Surgery also plays a major role in advanced disease.
Surgery of metastasic disease is recommended in G1–2
well-differentiated NETs if complete resection is deemed
feasible. If complete resection of metastatic disease is
performed no adjuvant treatment is recommended, but a
randomized trial addressing this question is being initiated.
Major cytoreductive therapy with palliative purposes may
be considered even if R0 is not achievable in patients with
extensive liver metastasis and hormonal syndrome refrac-
tory to medical therapy. Some advocate that this procedure
may also extend survival and could therefore be considered
Table 2 2010 WHO classification and grading of neuroendocrine








NET G1 \2 B2







NEC neuroendocrine carcinoma, NET neuroendocrine tumor, WHO
World Health Organization, HPF high-power field = 2 mm2 (at least
40 fieldsat 409 magnification evaluated in areas of highest mitotic
density)
a MIB1 antibody (% of 2,000 tumor cells in areas of highest nuclear
labeling). If Ki-67 index and mitotic index are inconsistent, choose
the highest grade
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Table 3 TNM classification (AJCC vs. ENETS)
AJCC TNM (7th edition) TNM proposed by ENETS
Pancreas
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: Tumor confined to pancreas B2 cm
T2: Tumor confined to pancreas [2 cm
T3: Tumor not confined to pancreas, but not involving coeliac trunk or
SMA
T4: Tumor invading coeliac trunk or SMA
Pancreas
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor confined to pancreas \2 cm
T2: Tumor confined to pancreas 2–4 cm
T3: Tumor confined to pancreas [4 cm or invading duodenum or bile duct
T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or wall of large
vessels (coeliac trunk or SMA)
Appendix
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor B2 cm
T2: Tumor [2–4 cm; caecum
T3: Tumor [4 cm; ileum
T4: Tumor perforating peritoneum or invading other organs or structures
Appendix
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor B1 cm invading submucosa and muscularis propria
T2: Tumor B2 cm invading submucosa and muscularis propria and/or minimally (B3 mm)
invading subserosa/mesoappendix
T3: Tumor [2 cm and/or invading subserosa/mesoappendix [3 mm
T4: Tumor invading peritoneum or other organs
Stomach
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: \0.5 mm confined to mucosa
T1: Tumor B1 cm invading lamina propria or submucosa
T2: Tumor [1 cm or invading muscularis propria
T3: Tumor invading subserosa
T4: Tumor perforating serosa or invading adjacent structures
Stomach
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Tumor in situ/dysplasia (\0.5 mm)
T1: Tumor B1 cm invading lamina propria or submucosa
T2: Tumor [1 cm or invading muscularispropria or subserosa
T3: Tumor penetrating serosa
T4: Tumor invading adjacent structures
Small intestine
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor B1 cm invading lamina propia or submucosa
T2: Tumor [1 cm or invading muscularis propia
T3: (a) Ampulla, duodenum: invading pancreas or retroperitoneum;
(b) jejunum, ileum: tumor invading subserosa
T4: Tumor perforating serosa or invading adjacent structures
Small intestine
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor B1 cm invading lamina propia or submucosa
T2: Tumor [1 cm or invading muscularispropria
T3: (a) Duodenum, ampulla, proximal jejunum: invading pancreas or retroperitoneum;
(b) distal jejunum and ileum: tumor invading subserosa
T4: Tumor invading peritoneum or other organs
Large intestine
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor B1 cm invading lamina propria or submucosa
T2: Tumor [1 cm or invading muscularispropria
T3: Tumor invading subserosa
T4: Tumor perforating serosa or invading adjacent structures
Large intestine
Tx: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Tumor invading mucosa or submucosa: T1a: \1 cm; T1b: 1–2 cm
T2: Tumor [2 cm or invading muscularispropria
T3: Tumor invading subserosa or pericolonic/perirectal fat






Stage IV Any TNM1






Stage IV Any TNM1
Small/large-cell enteric NECs: stage as carcinomas















Stage IV Any TNM1
AJCC American Joint Committee on Cancer, ENETS European Neuroendocrine Tumor Society, GI gastrointestinal, NEC neuroendocrine carcinoma, NET neuroendocrine
tumor, SMA superior mesenteric artery
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in non-functioning tumors. However, data in this regard are
not robust and need formal validation. Prophylactic cho-
lecystectomy to prevent cholelithiasis is recommended in
patients undergoing surgery if treatment with somatostatin
analogues (SSA) is anticipated. Surgery of the primary
tumor is often recommended in patients with metastatic
small-bowel NETs to avoid bowel obstruction due to the
neoplasm or to the fibrotic reaction commonly observed in
the adjacent mesentery. Perioperative prophylactic therapy
with SSA is mandatory in functional tumors to prevent
carcinoid crisis. Finally, liver transplantation is controver-
sial but can be considered in selected young patients with
well-differentiated liver-only metastases, resected primary
tumor and low Ki-67 index (\5 %), after a prolonged
surveillance period to exclude rapidly progressing tumors.
It may also be considered in patients with liver-only dis-
ease and a life-threatening functional syndrome.
Interventional radiology
In patients who are not suitable candidates for surgery,
regional control of liver metastases may be achieved by
different ablative techniques such as radiofrequency or
laser ablation, and cryotherapy, among others [3, 4, 10].
Reduction of tumor burden often leads to a reduction of
hormone secretion and, consequently, an improvement in
symptom control. Other locoregional approaches include
embolization of the hepatic artery by particles or cytotoxic
agents (trans-arterial chemoembolization, TACE) [11]. The
dual blood supply of the liver, with differential perfusion of
metastatic lesions and normal hepatocytes by the hepatic
artery and portal vein, respectively, make these therapeutic
strategies tolerable to the healthy liver and particularly
toxic to the cancer cell. They are generally employed with
palliative purposes in patients with slow growing G1–2
functional tumors refractory to medical therapy, but may
also be useful to reduce tumor burden and control tumor
progression in non-functioning tumors. Doxorubicin,
streptozocin, mitomycin and fluorouracil are commonly
used agents in this context, although adequately sized
randomized studies that properly evaluate the benefit-risk
ratio of chemoembolization with that of mechanical
embolization are lacking [12]. Clinical responses have been
reported in up to 80 % of the patients, and radiological
responses in about 50 %. Common adverse events include
pain, fever or elevation of liver enzymes. Severe compli-
cations occur in 10 % of cases and include acute liver or
renal failure, liver abscess, cholecystitis or carcinoid crisis.
Radioembolization is an alternative technique of liver-
directed therapy that is rapidly gaining acceptance and
involves the percutaneous transarterial injection of micron-
sized embolic particles loaded with a radioisotope (most
commonly yttrium-90), but well-designed, prospective
randomized trials comparing it to the other modalities are
lacking. Complications include nausea, fatigue, abdominal
pain, hepatic dysfunction, vascular or biliary injury,
fibrosis, radiation pneumonitis and gastrointestinal ulcers.
However, the risk of complications may be minimized by
meticulous pretreatment assessment, careful patient selec-
tion, and adequate dosimetry. Embolization is contraindi-
cated in patients with portal-vein thrombosis, liver
insufficiency, biliary obstruction or prior Whipple
procedure.
Systemic therapy
Patients with advanced disease have limited therapeutic
options. Indeed, NETs exhibit low susceptibility to con-
ventional cytotoxic therapy. Long-acting SSAs are cur-
rently the best option to provide symptomatic relief of
hormonal syndrome, and increasing clinical data indicate
that they also retard disease progression [13, 14]. Symp-
tomatic therapy in functional NETs may also include other
specific drugs depending upon the hormone or peptide
secreted in excess by the tumor, such as proton pump
inhibitors in gastrinomas, diazoxide or glucagon in insuli-
nomas, insulin or other pancreatic hormones in somato-
statinomas, etc. Other options to achieve disease control
include peptide-receptor radionuclide therapy, although
availability is still limited in many countries [15]. Ran-
domized trials are currently ongoing, the results of which
shall contribute to properly assess the benefit-risk balance
of this promising approach. Chemotherapy may be con-
sidered in certain disease settings, depending upon tumor
differentiation, bulk and kinetics, particularly in those of
pancreatic origin [16–18]. Finally, two targeted agents,
sunitinib and everolimus, have demonstrated in random-
ized placebo-controlled trials a clinically relevant antipro-
liferative effect in well-differentiated NETs of pancreatic
origin [19, 20]. Everolimus may also prolong progression-
free survival in non-pancreatic NETs [21]. However, the
magnitude of this effect is more limited. A number of other
targeted agents are currently in clinical development and
may add to the treatment armamentarium in the near future.
A therapeutic algorithm is proposed in Figs. 1, 2 and 3.
Somatostatin analogues and interferon
SSA remain the most effective drugs for symptom control
in functional GEP-NETs. Indeed, 70–80 % of patients
experience resolution of diarrhea or flushing, and about
40 % achieve biochemical response, although tumor
regression is rare. Nevertheless, two recent controlled trials
indicate they do have antiproliferative activity. The first
one, a randomized double-blind placebo-controlled trial
Clin Transl Oncol (2014) 16:1025–1034 1029
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conducted in 85 patients with well-differentiated G1 met-
astatic midgut NETs, showed that patients treated with
octreotide long-acting repeatable (LAR) (30 mg every
28 days) had a significantly longer time to tumor pro-
gression (14.3 months) than patients treated with placebo
(6 months) (HR 0.34, 95 % CI 0.20–0.59, P \ 0.001). The
greatest effect was observed in patients with low hepatic
tumor load and resected primary tumor [13]. The most
recent survival update of this trial did not show, however,
any difference in overall survival among study arms. Fur-
ther evidence of the antiproliferative effect of SSA has
been recently provided by the CLARINET study [14]. This
phase III, double-blind, placebo-controlled trial included
204 patients with well or moderately differentiated (Ki-67
\10 %) non-functioning GEP-NETs (45 % pancreatic,
36 % midgut, 7 % hindgut and 13 % of unknown primary),
that were randomly allocated to receive prolonged release
lanreotide (lanreotide autogel 120 mg) or placebo every
4 weeks. Treatment with lanreotide significantly prolonged
progression-free survival (PFS) over placebo (median not
reached with lanreotide versus 18 months with placebo,
HR 0.47, P \ 0.001). Of note, one-third of enrolled
patients had over 25 % liver involvement, and as opposed
to that observed in the PROMID study, patients with high
hepatic tumor load also benefited from lanreotide therapy.
The most convenient formulations are lanreotide autogel
(60, 90 or 120 mg) and octreotide LAR (10, 20 or 30 mg).
Currently recommended antiproliferative doses are octre-
otide LAR 30 mg or lanreotide autogel 120 mg every
28 days. When used for syndrome control starting doses
can be lower and then clinically monitored. Doses above
120 mg for Lanreotide autogel or 30 mg for Octreotide
LAR are off-label but can sometimes be needed in selected
cases. Short-acting subcutaneous octreotide is still neces-
sary to be used in combination with depot formulations
during the first 2 weeks of therapy until adequate plasma
therapeutic levels are achieved, and for rescue treatment in
carcinoid syndrome exacerbations. Adverse effects of SSA
are mild and manageable, and include malabsorption,
endocrine disturbances (hypothyroidism, hypoglycemia, or,
more commonly, hyperglycemia), pain and erithema at the
site of injection, hypersensitivity reactions and cholelithi-
asis on long-term use [3, 4].
Interferon is also effective in terms of symptomatic
control of the hormonal syndrome, but its use is limited by
substantial adverse effects (alopecia, anorexia, fatigue,
depression, liver toxicity, weight loss, fever, a flu-like
syndrome and myelosuppression). Although some small
randomized trials have shown a trend towards an improved
disease progression or overall survival when interferon was
added to SSA as first line treatment, this benefit was not
consistently observed in all trials or did not reach statistical
significance [3, 4]. For this reason it is generally indicated
after failure of other therapies.
Fig. 1 Therapeutic algorithm in GEP-NENs
1030 Clin Transl Oncol (2014) 16:1025–1034
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Fig. 3 Management of advanced/metastatic G1–G2 pancreatic NETs
A
B
Fig. 2 Management of advanced/metastatic G1–G2 enteric NETs
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Peptide-receptor radionuclide therapy
Patients with advanced disease and a positive octreoscan
may be considered for peptide receptor radionuclide ther-
apy (PRRT). PRRT primarily utilizes one of two radio-
isotopes, 90 Yttrium (90Y) or 177 Lutetium (177Lu),
attached to a SSA via the chelating agent 1,4,7,10-tetra-
azacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA). 90
Yttrium may be delivered as (90Y-DOTA0, Tyr3) Octre-
otide (90Y-DOTATOC) or as the newer (90Y-DOTA0,
Tyr3) Octreotate (90Y-DOTATATE). 90 Yttrium-labeled
SSAs have been reported to induce not only tumor stabil-
ization but also tumor regression (objective partial
responses) in up to 30 % of GEP-NETs [15]. However,
experience is limited to single institution selected series
and randomized controlled trials are currently ongoing and
shall provide more solid evidence regarding safety and
efficacy of this treatment modality. In addition, the non-
availability of this therapeutic strategy in most countries
further limits its widespread use. The appropriate timing of
this therapeutic intervention or the relative long-term
benefit-risk ratio compared to other treatment options are
key questions that remain unanswered. Alternatively, 131
Iodine-metaiodiobenzylguanidine (MIBG) therapy may be
considered in advanced tumors with a positive MIBG scan
(20–50 % of NETs).
Chemotherapy
Conventional cytotoxic therapy is considered as the first
treatment option for poorly differentiated or rapidly pro-
gressive advanced GEP-NETs. The combination of cis-
platin and etoposide is the most widely used chemotherapy
regimen in this setting, and is associated with a relatively
high (27–54 %) albeit short-lived response rate and a poor
survival (15–19 months). Well-differentiated tumors,
however, have a more indolent clinical course and exhibit
poor sensitivity to chemotherapy. Among them, radiolog-
ical, biochemical and clinical responses are more com-
monly encountered in pancreatic NETs (pNETs) than in
enteric or non-pancreatic NETs. For this reason, chemo-
therapy is considered an early therapeutic intervention in
advanced NETs of pancreatic origin only. In contrast,
chemotherapy plays a minor role in the management of
gastrointestinal NETs, being generally reserved for patients
with tumors refractory or progressive to other therapeutic
strategies (SSA, interferon, locoregional ablative therapy,
PRRT, etc.) and may likely soon be replaced by new
emergent targeted agents.
The most commonly employed regimens generally
combine streptozotocin with doxorubicin or 5-fluorouracil,
with response rates of 8–20 % reported in recent series
[3, 4]. These combination schedules showed improved
response rates and/or survival compared to single agent
streptozotocin in some old classical randomized clinical
trials [16–18]. However, these studies are methodologically
weak for current standards (small sample size, crucial
baseline clinical data not reported, lack of uniformity in the
assessment of tumor response), and antitumor efficacy of
these agents against placebo or best supportive care has
never been adequately evaluated in controlled trials. Other
active drugs in NETs include dacarbazine or temozolo-
mide. Temozolomide seems particularly active in O6-
methyl-guanine-methyl-transferase (MGMT)-deficient
tumors, an enzyme involved in the repair of temozolomide-
induced DNA damage. The combination of temozolomide
with capecitabine is a convenient and widely used oral drug
regimen, with a favorable toxicity profile and promising
results from small heterogeneous series [22]. However, the
safety and efficacy of these regimens have never been
properly assessed against other therapeutic options in this
context.
Novel targeted agents
Several recent adequately powered randomized trials have
for the first time demonstrated that there are agents able to
positively impact the outcome of this disease, in particular,
angiogenesis and mTOR inhibitors. Sunitinib, a tyrosine
kinase inhibitor that targets, among others, VEGFR,
PDGFR and c-kit, was evaluated in a randomized placebo-
controlled trial in patients with progressive well-differen-
tiated pancreatic NETs not suitable for curative surgery
[19]. Crossover of placebo patients to sunitinib at disease
progression was not initially permitted. About two-thirds of
patients had received prior chemotherapy and 20–22 %
were receiving concomitant SSA. This study aimed to
include 340 patients but was prematurely closed with 171
patients due to the excess of deaths observed in the placebo
arm. At that point, patients who had progressed on the
placebo arm became candidates for open-label sunitinib
therapy. Although objective responses were only observed
in 9 % of treated patients, PFS was significantly superior in
patients treated with sunitinib versus those receiving pla-
cebo (11.4 versus 5.5 months; HR 0.42; P = 0.001), as
well as overall survival (HR 0.41, P = 0.02) in the first
interim analysis. With further follow-up, and after 69 % of
patients had crossed over to sunitinib therapy, overall
survival still favored the sunitinib arm (30.5 versus
24.4 months), although this difference was no longer sta-
tistically significant (HR 0.74, P = 0.19).Common side
effects of drug included nausea, vomiting, asthenia and
hair-color changes, which were generally manageable, and
quality of life was not adversely affected by sunitinib
therapy. The main severe adverse events (grade 3–4) were
1032 Clin Transl Oncol (2014) 16:1025–1034
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neutropenia, hypertension and hand-foot syndrome, with
incidence rates of 6–12 %.
Regarding mTOR inhibitors, two large phase III trials
have explored safety and efficacy of everolimus in different
NET settings. The first one, the RADIANT-3 study, was
conducted in 410 patients with progressive advanced low
or intermediate grade pancreatic NETs who were randomly
assigned to everolimus or placebo with a double-blind
crossover study design [20]. Fifty percent of patients had
received prior chemotherapy. Again, objective responses
were low (5 %), but patients treated with everolimus had a
significantly longer PFS than those treated with placebo
(11.4 versus 5.4 months, HR 0.34, P \ 0.0001). No impact
was observed on survival, likely due to the fact that 73 %
of patients of the placebo arm crossed over to everolimus
upon disease progression. The safety profile of everolimus
was acceptable, being stomatitis, rash, diarrhea, fatigue,
and infections the most common side effects. About 5–7 %
of patients developed grade 3–4 toxicities, such as stoma-
titis, anemia and hyperglycemia. Pneumonitis and inter-
stitial lung disease (17 %) represent the most important
clinical concerns, although they were severe (grade 3–4) in
only 2 % of treated patients. In addition to its antiprolif-
erative effect, everolimus has proven effective in control-
ling refractory insulinoma syndrome. The second large
study, the RADIANT-2, included 429 patients with low or
intermediate grade advanced NETs with a history of car-
cinoid syndrome (the great majority of non-pancreatic
origin). These patients were randomly allocated to receive
octreotide LAR with placebo or with everolimus, with
cross-over to everolimus allowed at disease progression for
placebo allocated patients [21]. Median PFS evaluated by
local investigators was 12 versus 8.6 months for everoli-
mus versus placebo treated patients, respectively (HR 0.78,
95 % CI 0.62–0.98, P(one-tailed) = 0.036). Independent
central review documented a PFS improvement favoring
everolimus treatment of similar magnitude (16.4 versus
11.3 months; HR 0.77, 95 % CI 0.59–1.00; P(one-tailed)
= 0.026), but the observed difference missed the pre-
specified significance boundary (P B 0.0246). Similarly to
that observed in the prior study, a high proportion of
patients on the placebo arm crossed over to everolimus at
disease progression (58 %) and no differences were
observed in overall survival among study arms. Based on
these results, regulatory agencies granted marketing
authorization to sunitinib (2010) and everolimus (2011) for
the treatment of progressive advanced PNETs, but ever-
olimus was not approved for the treatment of NETs of non-
pancreatic origin. Another agent in advanced clinical
evaluation is bevacizumab, which is currently being tested
in a randomized trial against PEG-interferon in carcinoid
tumors, the results of which are eagerly awaited in the near
future [23].
In conclusion, sunitinib and everolimus are new treat-
ment options in patients with low or intermediate grade
pancreatic NETs in whom disease progression has been
documented. Whether these agents should be employed
before or after chemotherapy failure is a matter of debate.
The efficacy of both agents seems similar, although no
formal head-to-head comparisons exist nor are they
expected to be performed in the near future. Regarding the
use of everolimus in non-pancreatic functional NETs, no
firm recommendations can be made, as the reported benefit
is of lower magnitude and regulatory approval has not been
granted, within a clinical scenario with long survival and
scant therapeutic options. Efforts to provide predictive
biomarkers to help select subgroups of patients that are
more likely to benefit from each individual drug are cer-
tainly warranted.
Follow-up
Follow-up recommendations are based on expert opinion as
there is no solid evidence to support the type and frequency
of performance of specific procedures. Patients with
localized G1–2 NETs who have undergone complete
resection are recommended to be followed every
6–12 months the first 3 years, and then annually, at least up
to the 5th year following surgery, in order to detect
potentially resectable recurrences. Follow-up intervals
shall be shorter in patients with G3 NECs (every
3–6 months during the first 3 years). General tumor
markers (chromogranin A in G1–2 NETs or neuron-spe-
cific enolase in G3 NECs) and imaging procedures (CT
scan or MRI) shall be performed in these follow-up visits.
The role of octreoscan in this setting is controversial in the
absence of clinical, biochemical or radiological suspicion
of relapse. Specific markers (urinary 5-HIAA acid for
midgut NETs; insulin, gastrin or others for specific func-
tioning pNETs) may be also performed in tumors that
presented a hormonal syndrome or if clinically indicated.
Follow-up of patients with advanced disease shall be
customized depending upon tumor kinetics (Ki-67 prolif-
erative index and actual growth rate documented by serial
CT scans), treatment strategy, side effects of therapy and
general health condition. Visits may be done every
6 months for G1, slow growing tumors, in clinically stable
patients under low-toxic therapies (i.e., SSA). These
intervals, however, shall be scheduled far more frequently
for those with faster tumor kinetics and/or receiving more
toxic agents. In this last scenario, imaging procedures are
recommended to be performed every 3–6 months.
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